ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
- Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules a cross the blood-brain barrier
- ABL Bio to receive up to £77 million in upfront and near-term payments
SEONGNAM, South Korea, April 7, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. The agreement aims to develop multiple programs for novel targets across therapeutic modalities including antibody, polynucleotide or oligonucleotides, such as siRNA and ASOs, to address significant unmet medical needs of patients suffering from neurodegenerative conditions.
The blood-brain barrier (BBB) serves as a protective barrier that restricts the entry of harmful substances and agents into the brain and is considered a significant obstacle in the development of treatments for neurological diseases. ABL Bio's Grabody-B was developed to overcome the limitations of existing drugs that have difficulty crossing the BBB by targeting the Insulin-like Growth Factor 1 Receptor (IGF1R), facilitating drug penetration across the BBB and enabling efficient delivery into the brain.
Under the terms of the agreement, ABL Bio will receive up to £77.1 million in upfront and near-term payments, including an immediate upfront payment of £38.5 million, research milestones and potential program expansion. In total, ABL Bio is eligible to receive up to £2.075 billion in research, development, regulatory and commercialization milestone payments across multiple potential programs. ABL Bio will receive tiered royalties on net sales if products are successfully commercialized. As part of the agreement, ABL Bio will transfer Grabody-B-related technology and know-how to GSK, while GSK will assume responsibility for preclinical and clinical development, manufacturing, and commercialization.
Christopher Austin, SVP of Research Technologies, GSK, said "There is a critical need for new therapeutics to treat neurodegenerative brain diseases, which are rapidly increasing in prevalence due to the aging of the population. Many of the most promising new therapies are antibodies, which cannot efficiently reach the brain without a shuttle to get them across the BBB. This agreement reflects our commitment to innovative platform technologies to overcome the BBB and thus open entirely new opportunities for treating these devastating diseases, an important component of our emerging pipeline."
Sang Hoon Lee, CEO of ABL Bio said "This agreement underscores ABL Bio's leadership in BBB technology and its commitment to advancing transformative therapeutics in neurodegenerative diseases through strategic partnership with global pharmaceutical leaders like GSK. Additionally, this agreement will serve as a great opportunity to strengthen ABL Bio's position in the neurodegenerative disease treatment market through the potential commercialization of Grabody-B and to expand the modality areas where Grabody-B can be utilized. Given the increasing number of patients suffering from neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, we hope this partnership will accelerate the development of innovative treatments and bring renewed hope to patients worldwide."
About ABL Bio
ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform 'Grabody'. Clinical projects for 7 pipelines, including ABL301, ABL001 (tovecimig), ABL111 (givastomig), ABL503 (ragistomig), ABL105, ABL202, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In case of ABL001 (tovecimig), has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. In addition, ABL111 (givastomig), co-developed with I-Mab, is expected to disclose the top-line data from the Phase 1b clinical trial in 2025, evaluating the triple combination therapy with nivolumab and chemotherapy. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 days ago
- Korea Herald
Where the Industry Connects: Bangkok's Building Construction Technology Expo Announces Robust Lineup of Conferences and Workshops
BANGKOK, Aug. 1, 2025 /PRNewswire/ -- Asia's leading Building Construction Technology Expo (BCT Expo) returns to Bangkok with a line-up of dynamic conferences, workshops and industry networking opportunities, taking place from 3 rd to 5 th September at IMPACT Exhibition and Convention Centre. The Southeast Asia construction market was valued at around US $538 billion in 2024, with forecasts pointing to 6% to 6.2% annual Compound Annual Growth Rate (CAGR) through 2028. For Thailand, the construction industry is a significant driver of growth, contributing substantially to the country's economy. It is against this market backdrop that BCT Expo 2025 is organized to serve as Southeast Asia's premier "Construction & Mining Meeting Place". This event is set to welcome over 150 exhibiting brands and 4,000 industry professionals across the entire spectrum of the building, construction and mining sector for 3 days of business exchanges, partnerships and opportunities. To further connect the industry, BCT Expo is bringing together a robust line-up of free-to-attend conferences and workshop with over 39 keynote and panel discussion sessions, featuring over 45 speakers and industry gurus, who will gather to share and discuss the latest trends, know-hows, innovation and issues shaping the future of the Southeast Asian building and construction industry and markets. These forum sessions will touch on a range of insightful topics in sectors such as mining, tall buildings and vertical cities, construction AI and robotics, construction safety, smart financing, green construction, smart facility management, heavy equipment and technology trends, pre-cast technology, piling, and concrete, just to name a few. It is known that Thailand construction is one of the most dangerous sectors, but BCT Expo is committed to raising safety standards by equipping engineers and contractors with practical knowledge and certifications to build a safer future. BCT Expo aims to uplift the construction safety standards of Thailand, through a series of certification workshops and skill development courses on fire and safety, and work environment hazard assessments. These courses, to be conducted by the Chonburi's Safety Officers Club will be attended by safety officers, engineers, and contractors At the same time, the Thai Lifting Engineering, Crane and Heavy Equipment Association will provide certified practical workshops, with professional development units (PDUs) points for participants, on safety knowledge and practices on crane and heavy construction machinery operations. BCT Expo 2025 will also see the conduct of a whole range of interactive industry activities across its exhibition show floor that will include: BCT Expo 2025 will provide attendees with plenty of business exchanges, in-depth and insightful understanding on the dynamics of the growing building and construction market in Thailand and Southeast Asia. In addition, the event will offer plenty of opportunities networking opportunities for attendees to renew and seek new networks. Register now at to secure your complimentary pass and make the most of your visit. IMPACT Exhibition Management Co. Ltd. IMPACT Exhibition Management Co., Ltd. is the leading exhibition organizer in Thailand. We organize and manage professional trade and public exhibitions, conferences, meetings and training, working in hand with international trade associations, organizers, and corporations across a broad spectrum of industries.
Korea Herald
2 days ago
- Korea Herald
Under the Patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan ADFW 2025 Set to Double in Size at New Location
ABU DHABI, UAE, Aug. 1, 2025 /PRNewswire/ -- Under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, the Crown Prince of Abu Dhabi, and Chairman of the Executive Council, Abu Dhabi Finance Week (ADFW), the largest financial event in the region, will return for an ambitious fourth edition, which will see it double in size, and cement its status as a top global gathering of financial leaders. The flagship financial event of the MEASA region, hosted by ADGM, the international financial centre of Abu Dhabi and headlined by ADQ, will run from 8 th December to 1 1 th December 202 5. The agenda for the 2025 edition is designed around the theme of ' Engineering the Capital Network '. 'Engineering' highlights the use of new technologies in re-architecting modern finance, particularly artificial intelligence and quantum technologies. 'Capital Network' reflects the evolving flows and dynamics of financial centres. In a world where gravitational forces from economic giants like China, India, the U.S., and Europe have increasingly centred the nexus of the global market in the Gulf, Abu Dhabi is at the heart of global capital flows and the destination of choice for global participants. The theme also underscores Abu Dhabi's evolution from primarily a capital exporter to a two-way system of capital flows, powered by leading institutions and a world-class regulatory ecosystem at ADGM. Commenting on this year's ADFW, His Excellency Ahmed Jasim Al Zaabi, Chairman of ADGM, said, " ADFW 2025 is set to be our most ambitious edition of this hugely successful event. With this year's edition to be held at a new location and doubl e in size from last year's ADFW venue, we are setting a new standard for financial gatherings in the region and beyond. This reflects Abu Dhabi's growing influence in global capital markets and our commitment to continue creating a truly international financial platform." ADFW has become a launchpad and stage for international deals, partnerships and major announcements. In 2023, global financial institutions representing USD 450 billion of assets under management (AUM) announced at the event that they were setting up in ADGM. This momentum continued in 2024 and during last year's ADFW, institutions representing USD 650 billion in AUM announced they were joining the ADGM community. ADFW 2024 gathered over 20,000+ global leaders, experts, executives, and policymakers, collectively controlling USD 42.5 t rillion of assets, and featured over 350 sessions across more than 60 industry-shaping events and strategic forums, with leaders gathering to address major market challenges in economics, asset management, technology and sustainability. Last year, Abu Dhabi's sovereign wealth funds managed an unparalleled USD 1.7 trillion of assets, cementing its status as the world's wealthiest city and empowering its financial might to drive long-term investments and economic resilience.
Korea Herald
2 days ago
- Korea Herald
FORTUNE ANNOUNCED FORTUNE CHINA 500 RANKINGS, SERES HAD THE BIGGEST LEAP IN 2025 RANKINGS DRIVEN BY AITO BRAND GROWTH
SERES fastest-rising company of Fortune China 2025, outpacing peers in China's competitive NEV market. CHONGQING, China, Aug. 1, 2025 /PRNewswire/ -- SERES has emerged as this year's biggest mover on the 2025 Fortune China 500 list, vaulting to 169th place, a jump of 235 spots from last year's 404th position. This dramatic rise underscores SERES' rapid growth in the highly competitive new energy vehicle (NEV) market. In 2024, SERES' revenue surged to RMB 145.2 billion (approx. US$20.2 billion), up 305% year on year, while net profit attributable to shareholders reached RMB 5.95 billion. The company's annual NEV sales reached 420,000 units, an increase of more than 182%, driving its gross profit margin for the NEV business to 26.21%—a new record high. Fortune highlighted that amid rapid NEV sector growth and intensifying competition, SERES' success was driven by its close collaboration with partners, enabling continuous product innovation and operational excellence. AITO Brand Fuels Growth AITO, the luxury NEV brand founded in 2021, has been a core growth driver. In just 40 months, AITO achieved over 700,000 cumulative deliveries, setting a new record for delivery speed among luxury NEV brands in China including over 200,000 units delivered of the flagship model AITO M9 and deliveries of the recently launched AITO M8 already surpassing 40,000 units. In addition, the new AITO M7 series has maintained its position as the top-selling model in the highly competitive RMB 300,000 (approx. US$42,000) segment from 2024 to the present, setting a new record for Chinese luxury new energy brands. These milestones demonstrate the brand's ability to deliver advanced intelligent luxury experiences while accelerating its expansion in both domestic and overseas markets. With its strong manufacturing capabilities, deep collaboration on intelligent vehicle technologies, and a growing product portfolio, SERES is well-positioned to further strengthen its leadership in China's NEV market and make significant strides globally.
